Multiple cerebral lesions complicating therapy with interleukin-2

被引:34
作者
Karp, BI
Yang, JC
Khorsand, M
Wood, R
Merigan, TC
机构
[1] NCI, NIH, BETHESDA, MD 20892 USA
[2] UNIV WISCONSIN, CTR COMPREHENS CANC, MADISON, WI 53706 USA
[3] STANFORD UNIV, CTR AIDS RES, STANFORD, CA 94305 USA
关键词
D O I
10.1212/WNL.47.2.417
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We reviewed the records and radiologic studies of eight patients who developed new focal neurologic abnormalities while receiving interleukin-2 (IL2)-based immunotherapy for malignancy or HIV infection. Initial confusion and delirium in the patients evolved into coma, ataxia, hemiparesis, seizures, and cortical syndromes including aphasia, apraxia, and cortical blindness. Imaging studies showed multiple white and gray matter lesions with a predilection for the occipital poles, centrum semiovale, and cerebellum. After cessation of IL2 treatment, seven patients improved to normal or near-normal neurologic function paralleled by resolution of the lesions on scans. One patient improved only minimally. Possible etiologies for the lesions include an IL-induced cerebral vasculopathy, a direct toxic effect of IL2, or immunologically mediated damage.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 54 条
[1]   LOCALIZATION OF INTERLEUKIN-2 IMMUNOREACTIVITY AND INTERLEUKIN-2 RECEPTORS IN THE RAT-BRAIN - INTERACTION WITH THE CHOLINERGIC SYSTEM [J].
ARAUJO, DM ;
LAPCHAK, PA ;
COLLIER, B ;
QUIRION, R .
BRAIN RESEARCH, 1989, 498 (02) :257-266
[2]   THE INTERLEUKIN-1-ALPHA, INTERLEUKIN-1-ALPHA, AND INTERLEUKIN-2 DO NOT ACUTELY DISRUPT THE MURINE BLOOD-BRAIN-BARRIER [J].
BANKS, WA ;
KASTIN, AJ .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1992, 14 (04) :629-636
[3]   STIMULATION OF OLIGODENDROGLIAL PROLIFERATION AND MATURATION BY INTERLEUKIN-2 [J].
BENVENISTE, EN ;
MERRILL, JE .
NATURE, 1986, 321 (6070) :610-613
[4]   TRANSIENT FOCAL NEUROLOGIC DEFICITS COMPLICATING INTERLEUKIN-2 THERAPY [J].
BERNARD, JT ;
AMERISO, S ;
KEMPF, RA ;
ROSEN, P ;
MITCHELL, MS ;
FISHER, M .
NEUROLOGY, 1990, 40 (01) :154-155
[5]   POLYETHYLENE-GLYCOL CONJUGATED INTERLEUKIN-2 - CLINICAL AND IMMUNOLOGICAL EFFECTS IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA [J].
BUKOWSKI, RM ;
YOUNG, J ;
GOODMAN, G ;
MEYERS, F ;
ISSELL, BF ;
SERGI, JS ;
MCLAIN, D ;
FYFE, G ;
FINKE, J .
INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) :211-217
[6]  
BYRD RL, 1981, CANCER, V47, P37, DOI 10.1002/1097-0142(19810101)47:1<37::AID-CNCR2820470108>3.0.CO
[7]  
2-8
[8]  
COTRAN RS, 1988, J IMMUNOL, V140, P1883
[9]   THE NEUROPSYCHIATRIC EFFECTS OF TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS [J].
DENICOFF, KD ;
RUBINOW, DR ;
PAPA, MZ ;
SIMPSON, C ;
SEIPP, CA ;
LOTZE, MT ;
CHANG, AE ;
ROSENSTEIN, D ;
ROSENBERG, SA .
ANNALS OF INTERNAL MEDICINE, 1987, 107 (03) :293-300
[10]  
DESARRO G, 1991, INT J NEUROSCI, V59, P67